Several industry executives and doctors ET spoke to said at the moment, while cases are rising, the need for Paxlovid hasn’t been felt as cases are mild and they also pointed to the bitter experience they had with molnupiravir in third wave, where they were left with lots of unsold stock and had to take write-offs.
